Wave Life Sciences Q3 revenue jumps, beats estimates
WVE•Wave Life Sciences reported Q3 revenue of $13.16 million, above the $4.32 million analyst estimate, and a net loss of $61.91 million, narrower than the $67.83 million expected. The company said revenue growth was primarily driven by a $12 million milestone payment from GSK.
1. Q3 results
Wave Life Sciences reported Q3 revenue of $13.16 million, compared with analyst estimates of $4.32 million. Its net loss was $61.91 million, versus the $67.83 million expected, while operating expenses were $79.21 million.
2. Pipeline and cash
The company said revenue growth was primarily due to a $12 million milestone payment earned from GSK for candidate selection in their collaboration program. Wave plans a registrational trial for WVE-006 in AATD, including an interim analysis for accelerated approval, and expects its cash runway to fund operations into Q3 2028. It also plans to initiate a WVE-007 post-incretin maintenance trial in Q4 2026.
